Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 4/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | BLM | P54132 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11332500 | 0.87 | MAPT (0.68) | KMT2AMEN1MAPK1GAAMAPT | |
| SCHEMBL11065195 | 0.79 | NPC1 (0.57) | EPHX1KMT2AMEN1MAPK1HTT | |
| SCHEMBL16119683 | 0.79 | EPHX1 (0.81) | EPHX1KMT2AMEN1GAAMAPT | |
| SCHEMBL11161985 | 0.78 | EPHX1 (0.70) | EPHX1KMT2AMEN1GAAMAPT | |
| SCHEMBL11162854 | 0.77 | EPHX1 (0.64) | EPHX1KMT2AMEN1HTTGAA | |
| SCHEMBL17610005 | 0.76 | EPHX1 (0.66) | EPHX1KMT2AMEN1MAPTALDH1A1 | |
| SCHEMBL16127142 | 0.76 | EPHX1 (0.62) | EPHX1KMT2AMEN1MAPTALDH1A1 | |
| SCHEMBL5713610 | 0.76 | ALDH1A1 (0.62) | EPHX1KMT2AMEN1HTTMAPT | |
| SCHEMBL17891689 | 0.76 | ALDH1A1 (0.69) | EPHX1KMT2AMEN1HTTMAPT | |
| SCHEMBL6809740 | 0.76 | HDAC1 (0.64) | EPHX1KMT2AMEN1GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970248-B1 | COUMARIN DERIVATIVES AND METHODS OF USE IN TREATING CYSTIC FIBROSIS, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, AND MISFOLDED PROTEIN DISORDERS | DISCOVERYBIOMED INC (US) | 2020-04-22 | — | — | EP | disclosed |
| US-10369145-B2 | Coumarin derivatives and methods of use in treating hyperproliferative diseases | DISCOVERYBIOMED, INC. (US) | 2019-08-06 | — | — | US | disclosed |
| US-9815825-B2 | Coumarin derivatives and methods of use in treating cystic fibrosis, chronic obstructive pulmonary disease, and misfolded protein disorders | DISCOVERYBIOMED, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-20160038475-A1 | COUMARIN DERIVATIVES AND METHODS OF USE IN TREATING HYPERPROLIFERATIVE DISEASES | DISCOVERYBIOMED, INC. (US) | 2016-02-11 | — | — | US | disclosed |
| US-20160024065-A1 | COUMARIN DERIVATIVES AND METHODS OF USE IN TREATING CYSTIC FIBROSIS, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, AND MISFOLDED PROTEIN DISORDERS | DISCOVERYBIOMED, INC. (US) | 2016-01-28 | — | — | US | disclosed |
| WO-2014152213-A2 | COUMARIN DERIVATIVES AND METHODS OF USE IN TREATING CYSTIC FIBROSIS, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, AND MISFOLDED PROTEIN DISORDERS | DISCOVERYBIOMED, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014152278-A2 | COUMARIN DERIVATIVES AND METHODS OF USE IN TREATING HYPERPROLIFERATIVE DISEASES | DISCOVERYBIOMED, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024065-A1 | COUMARIN DERIVATIVES AND METHODS OF USE IN TREATING CYSTIC FIBROSIS, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, AND MISFOLDED PROTEIN DISORDERS | CFTR, SLC47A1, ABCB11 | EPHX1 3072/4885KMT2A 4821/4885MEN1 4704/4885 |
| US-10369145-B2 | Coumarin derivatives and methods of use in treating hyperproliferative diseases | HSP90B1, HSPD1, HSPE1 | EPHX1 3406/4885KMT2A 4677/4885MEN1 3455/4885 |
| US-20160038475-A1 | COUMARIN DERIVATIVES AND METHODS OF USE IN TREATING HYPERPROLIFERATIVE DISEASES | HSP90B1, HSPD1, HSPE1 | EPHX1 3406/4885KMT2A 4677/4885MEN1 3455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.